Mate I. Milak, MD
Associate Professor of Psychiatry at CUMC
Dr. Milak first became involved in neuroscience upon entering medical school, when he joined a group working on motor control in the context of adaptation to micro-gravity in animal models. After medical school he moved to the Barrow Neurological Institute (BNI) in Phoenix Arizona to study learning and memory in motor control. He became involved in human research and his interest shifted toward higher cognitive functions and their deficits in brain disorders. To pursue a career in clinical research studying the neurobiology of cognitive deficits in mental illness, Dr. Milak decided to complete his residency training in psychiatry. After residency, he joined the Columbia University Department of Psychiatry in July 2002 as a fellow. In 2006, he joined the faculty after obtaining a Career Development Grant from the NIMH. Since at Columbia, Dr. Milak has been working on developing and applying molecular brain-imaging techniques in exploring the etiology and pathophysiology of psychiatric disorders. His current work focuses on the antidepressant mechanism of action of NMDA antagonists like ketamine.
3 East 68th Street Office
3 East 68th Street
Suite 4 New York, NY 10065
Phone: (646) 583-1273
Public Transportation: Yes
Disabled Access: Yes
Herbert Pardes Building of the New York State Psychiatric Institute
1051 Riverside Drive
Room PI 42 New York, NY 10032
Phone: (212) 543-5553
Public Transportation: Yes
Disabled Access: Yes
Utilizing molecular brain imaging techniques in the search of biomarkers, endophenotypes and their utility in diagnosing, understanding and predicting treatment outcome of major brain disorders.
Major depressive disorder (MDD) is a highly prevalent illness, affecting over 14 million American adults annually. It was the fourth leading cause of disability globally in 2002, as assessed by disease-adjusted-life years according to the World Health Organization. By 2030, MDD is projected to become the second leading cause of disability as assessed by this measure, second only to HIV/AIDS. In the US, MDD is already the leading cause of disability for ages 15-44, with estimated total annual costs of $US 43.7 billion in 1990. A more recent estimate puts the annual population-level workplace cost of MDD in the US at $36.6 billion, not counting healthcare cost. Compounding the disease burden and the related cost of illness in MDD is the several week delay between initiation of treatment and onset of therapeutic action of currently available treatments. Shortening this delay to clinically significant improvement in antidepressant treatment of MDD is a major unmet challenge.
Studies report that a single intravenous sub-anesthetic dose of ketamine (an NMDA receptor antagonist) can bring about full remission in hours, even in treatment-resistant MDD. Aspects of ketamine's mechanism of therapeutic action have been fairly well established. It has been demonstrated that ketamine rapidly activates the mammalian target of rapamycin, mTOR. When mTOR signaling is activated, within minutes a rapid increase in synaptic signaling proteins, the number of newpine dendrites, synaptogenesis, and increased motor activity in animal models of depression ensues. although many other pathways are activated, these ketamine-induced changes are only stopped when either the AMPA receptors or the downstream mTOR signaling is blocked. This leads to the question of how ketamine activates the AMPA receptors, which are necessary for the activation of mTOR. Our preliminary data suggests that ketamine, by blocking NMDA receptors, induces a robust acute increase (more than 60%) in glutamate (Glu;the engogenous agonist of NMDA and AMPA receptors) and gamma aminobutyric acid (GABA) levels in the anterior cingulate cortex (ACC) as measured by proton magnetic resonance spectroscopy (1H MRS). We hypothesize that not ketamine directly, but this increase in Glu levels, triggered by blocking the NMDA receptors, is responsible for the activation of AMPA receptors and subsequently mTOR signaling. Studying ketamine's mechanism of action could help optimize the use of ketamine, develop better maintenance strategies, and guide development of other more easily administered medications working through the molecular targets suggested by the results of these experiments. The objective of the proposed project is to study the relationship between the ketamine-induced improvement of MDD and the Glu and GABA responses to ketamine and to compare the Glu and GABA responses to ketamine in MDD and healthy subjects to further elucidate the pathophysiology of MDD. To study this we designed a randomized, placebo-controlled, double-blind study with several different doses of ketamine.
Supervision of medical residents.